Literature DB >> 32507039

Effects of Ramipril on the Aldosterone/Renin Ratio and the Aldosterone/Angiotensin II Ratio in Patients With Primary Aldosteronism.

Zeng Guo1, Marko Poglitsch2, Diane Cowley1, Oliver Domenig2, Brett C McWhinney3, Jacobus P J Ungerer3,4, Martin Wolley1, Michael Stowasser1.   

Abstract

The aldosterone/renin ratio (ARR) is currently considered the most reliable approach for case detection of primary aldosteronism (PA). ACE (Angiotensin-converting enzyme) inhibitors are known to raise renin and lower aldosterone levels, thereby causing false-negative ARR results. Because ACE inhibitors lower angiotensin II levels, we hypothesized that the aldosterone/equilibrium angiotensin II (eqAngII) ratio (AA2R) would remain elevated in PA. Receiver operating characteristic curve analysis involving 60 patients with PA and 40 patients without PA revealed that the AA2R was not inferior to the ARR in screening for PA. When using liquid chromatography-tandem mass spectrometry to measure plasma aldosterone concentration, the predicted optimal AA2R cutoff for PA screening was 8.3 (pmol/L)/(pmol/L). We then compared the diagnostic performance of the AA2R with the ARR among 25 patients with PA administered ramipril (5 mg/day) for 2 weeks. Compared with basally, plasma levels of equilibrium angiotensin I (eqAngI) and direct renin concentration increased significantly (P<0.01 or P<0.05) after ramipril treatment, whereas eqAngII and ACE activity (eqAngII/eqAngI) decreased significantly (P<0.01). The changes of plasma renin activity and plasma aldosterone concentration in the current study were not significant. On day 14, 4 patients displayed false-negative results using ARR_direct renin concentration (plasma aldosterone concentration/direct renin concentration), 3 of whom also showed false-negative ARR_plasma renin activity (plasma aldosterone concentration/plasma renin activity). On day 15, 2 patients still demonstrated false-negative ARR_plasma renin activity, one of whom also showed a false-negative ARR_direct renin concentration. No false-negative AA2R results were observed on either day 14 or 15. In conclusion, compared with ARR which can be affected by ACE inhibitors causing false-negative screening results, the AA2R seems to be superior in detecting PA among subjects receiving ACE inhibitors.

Entities:  

Keywords:  aldosterone; angiotensins; mass spectrometry; renin; renin-angiotensin system

Year:  2020        PMID: 32507039     DOI: 10.1161/HYPERTENSIONAHA.120.14871

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  5 in total

1.  Poor Performance of Angiotensin II Enzyme-Linked Immuno-Sorbent Assays in Mostly Hypertensive Cohort Routinely Screened for Primary Aldosteronism.

Authors:  Agnieszka Łebek-Szatańska; Lucyna Papierska; Piotr Glinicki; Wojciech Zgliczyński
Journal:  Diagnostics (Basel)       Date:  2022-04-30

2.  Suspected primary hyperreninism in a cat with malignant renal sarcoma and global renin-angiotensin-aldosterone system upregulation.

Authors:  Jeremy Evans; Jessica Ward; Oliver Domenig; Jonathan P Mochel; Kate Creevy
Journal:  J Vet Intern Med       Date:  2021-12-03       Impact factor: 3.333

3.  Sacubitril/Valsartan and Ivabradine Attenuate Left Ventricular Remodelling and Dysfunction in Spontaneously Hypertensive Rats: Different Interactions with the Renin-Angiotensin-Aldosterone System.

Authors:  Fedor Simko; Tomas Baka; Peter Stanko; Kristina Repova; Kristina Krajcirovicova; Silvia Aziriova; Oliver Domenig; Stefan Zorad; Michaela Adamcova; Ludovit Paulis
Journal:  Biomedicines       Date:  2022-07-31

4.  Associations of central and peripheral blood pressure with the renin-angiotensin-aldosterone system in healthy young adults: the African-PREDICT study.

Authors:  Lebo F Gafane-Matemane; Nametsegang L Mokae; Yolandi Breet; Marko Poglitsch; Aletta E Schutte
Journal:  Hypertens Res       Date:  2020-10-30       Impact factor: 3.872

5.  Renin-angiotensin-aldosterone system peptide profiles in patients with COVID-19.

Authors:  Alexander Kutz; Anna Conen; Claudia Gregoriano; Sebastian Haubitz; Daniel Koch; Oliver Domenig; Luca Bernasconi; Beat Mueller; Philipp Schuetz
Journal:  Eur J Endocrinol       Date:  2021-04       Impact factor: 6.558

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.